Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 800 results for "warner chilcott"

Actavis plans name change to Allergan Drugmaker Actavis is planning to change its name as it draws closer to finishing another big deal, the $66 billion purchase of Botox maker Allergan that it announced last fall
Mail.com

8-K - Warner Chilcott Ltd (0001620602) (Filer)

Filing Date 2015-03-10 Accepted 2015-03-10 17:28:53 Documents 4 Period of Report 2015-03-10 Filing Date Changed 2015-03-10 Items Item 8.01: Other Events Item 9.01: Financial Statements SEC Filings, 2 weeks ago
[x]  

WARNER CHILCOTT LTD - 10-K - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Except for the historical information contained herein, the following discussion contains forward-looking statements that are subject to known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from ...
 Pharmacy Choice1 month ago ACTAVIS PLC - 10-K - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS  Pharmacy Choice1 month ago

Warner Chilcott Co, LLC v. Teva Pharms. USA, Inc

Winter 2014 Case Name: . , Nos. 2014-1439, 2014-1441, 2014-1444, 2014-1445, 2014-1446, 2014 U.S. App. LEXIS 21946 (Fed. Cir. Nov. 18, 2014) (Circuit Judges Lourie, Reyna and Taranto presiding; Opinion by Lourie, J.) (appeal from D. Del., Stark, ...
 JD Supra1 month ago

Judge Sides With Teva and Strikes Down Actavis's Atelvia Patents

A federal judge has sided with a Paragraph IV ANDA from Teva and struck down the patents protecting Actavis subsidiary Warner Chilcott's postmenopausal osteoporosis drug Atelvia. The New Jersey district court judge ruled in a patent ...
 FDA News2 weeks ago BRIEF-U.S. judge for Teva in patent litigation concerning Atelvia  Reuters UK3 weeks ago
Nasdaq

Cynapsus Therapeutics Recaps 2014 Annual Results [Professional Services Close - Up]

Cynapsus Therapeutics reported financial results for the year ended December 31, 2014. "In 2014 we made significant progress advancing our strategic plan in key areas, including the clinical development of APL-130277 and strengthening our ...
 Pharmacy Choice1 day ago Cynapsus Therapeutics Posts 2014 Annual Results  Individual.com1 week ago Cynapsus loses $10.81-million in 2014  Stockwatch1 week ago Cynapsus Therapeutics Inc. (CYNAF: OTCQX International) | Cynapsus Therapeutics Reports 2014 Annual Results  Pink Sheets1 week ago
[x]  

Actavis scoops rival for €62bn

A Dublin-headquartered pharmaceutical giant has completed its takeover of a US rival for $66bn (€62bn). Actavis sealed the deal to acquire Allergan in a cash and equity transaction in a move that catapults the combined entity into the world's ...
 Irish Examiner1 week ago

Puerto Rico manufacturing base to grow with AbbVie expansion

AbbVie ($ABBV) this week announced plans to expand in Puerto Rico, investing $30 million and creating up to 100 jobs on the island that has seen hits and misses in recent years from pharma manufacturers. The company received $1 million in ...
 FiercePharmaManufacturing1 week ago

Actavis Slashing More Than 400 Jobs in New York

March 18, 2015 By Riley McDermid and Mark Terry , BioSpace.com Breaking News Staff Irish drugmaker Actavis plc ( ACT ) is once again winnowing the workforce of newly acquired Forest Laboratories, Inc. ( FRX ) saying today it will be laying ...
 BioSpace1 week ago Actavis (ACT) Touts Potential $6 Billion Pipeline at Investor Meeting 2/19/2015  ClinicSpace1 month ago
CNBC

Cramer: Stocks to buy ahead of the Fed

Jim Cramer has spent much of his career anticipating trends in the stock market and teaching investors how to best profit from them. However, now the market has become a whole new ballgame, and all the trends have been thrown out the window. ...
 CNBC1 week ago
SPi World News

Fitch Downgrades Allergan's Ratings; Affirms Actavis at 'BBB-'; Outlook Stable

Fitch Ratings has affirmed the ratings for Actavis plc (Actavis; NYSE: ACT ), including the Long-term Issuer Default Rating (IDR), at 'BBB-'. Fitch has also downgraded the ratings for Allergan, Inc. (Allergan), including the ...
 Crawford Financial Planning1 week ago Fitch Downgrades Allergan''s Ratings; Affirms Actavis at ''BBB-''; Outlook Stable  Nasdaq1 week ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - warner chilcott
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less